The role of alemtuzumab in the development of secondary autoimmunity in multiple Sclerosis: a systematic review.

ABSTRACT:

Background

Secondary autoimmune disease (SAID) in the context of alemtuzumab treatment is one of the main safety concerns that may arise following administration in people with multiple sclerosis (pwMS). Contributing factors underlying this adverse event are not well understood. The purpose of this systematic review was to appraise the literature investigating the role of alemtuzumab in the development of SAID in pwMS following treatment and identify potential biomarkers/ risk factors that may be predictive of onset of this manifestation.

Methods

Relevant publications were retrieved from PubMed, Embase, and Web of Science using a three-pronged search strategy containing the following keywords: "multiple sclerosis"; "alemtuzumab"; and "autoimmunity". Studies that fulfilled th

SUBMITTER: Jimenez-Sanchez S 

PROVIDER: S-EPMC11528992 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature